Giovanni Barosi

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Claire Harrison, Jean‐Jacques Kiladjian, Haifa Kathrin Al‐Ali et al. · New England Journal of Medicine · 2012 · 1.8K citations · Full text

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

Francisco Cervantes, Brigitte Dupriez, Arturo Pereira et al. · Blood · 2008 · 1.2K citations · Full text

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Ayalew Tefferi, Jüergen Thiele, Attilio Orazi et al. · Blood · 2007 · 857 citations · Full text

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Tiziano Barbui, Giovanni Barosi, Gunnar Birgegård et al. · Journal of Clinical Oncology · 2011 · 825 citations · Full text

Mixed-phenotype Acute Leukemia, European Leukemianet, Pathology +16

Mutations and prognosis in primary myelofibrosis

A. M. Vannucchi, T L Lasho, Paola Guglielmelli et al. · Leukemia · 2013 · 739 citations

Hematological Malignancy, Hematology, Pathology +4